TY - JOUR
T1 - Structural basis for the drug extrusion mechanism by a MATE multidrug transporter
AU - Tanaka, Yoshiki
AU - Hipolito, Christopher J.
AU - Maturana, Andrés D.
AU - Ito, Koichi
AU - Kuroda, Teruo
AU - Higuchi, Takashi
AU - Katoh, Takayuki
AU - Kato, Hideaki E.
AU - Hattori, Motoyuki
AU - Kumazaki, Kaoru
AU - Tsukazaki, Tomoya
AU - Ishitani, Ryuichiro
AU - Suga, Hiroaki
AU - Nureki, Osamu
N1 - Funding Information:
Acknowledgements We are grateful to the beam-line staff at BL32XU of SPring-8 for assistance in data collection (proposals 2011B1062, 2012A1087 and 2012B1161), and the RIKEN BioResource Center (Ibaraki, Japan) for providing the P. furiosus genomic DNA. We are also grateful to N. Dohmae and Y. Sugita (RIKEN Advanced Science Institute, Japan)for discussions. This work was supported bythe Japan Society for the Promotion of Science (JSPS) through its ‘Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST program)’ to O.N.; by the Core Research for Evolutional Science and Technology Program ‘The Creation of Basic Medical Technologies to Clarify and Control the Mechanisms Underlying Chronic Inflammation’ of Japan Science and Technology Agency to O.N.; and by a Grant-in-Aid for Scientific Research (S) (24227004) and a Grant-in-Aid for Young Scientists (A) (22687007)fromMEXTtoO.N.and R.I.,respectively. Thisworkwasalsosupported bya JSPS Grant-in-Aid for the Specially Promoted Research (21000005) and MEXT Platform for Drug Discovery, Informatics, and Structural Life Science to H.S., and a Grant-in-Aid for JSPS post-doctoral fellows to C.J.H. (P11344).
PY - 2013/4/11
Y1 - 2013/4/11
N2 - Multidrug and toxic compound extrusion (MATE) family transporters are conserved in the three primary domains of life (Archaea, Bacteria and Eukarya), and export xenobiotics using an electrochemical gradient of H+ or Na+ across the membrane. MATE transporters confer multidrug resistance to bacterial pathogens and cancer cells, thus causing critical reductions in the therapeutic efficacies of antibiotics and anti-cancer drugs, respectively. Therefore, the development of MATE inhibitors has long been awaited in the field of clinical medicine. Here we present the crystal structures of the H+-driven MATE transporter from Pyrococcus furiosus in two distinct apo-form conformations, and in complexes with a derivative of the antibacterial drug norfloxacin and three in vitro selected thioether-macrocyclic peptides, at 2.1-3.0 Å resolutions. The structures, combined with functional analyses, show that the protonation of Asp 41 on the amino (N)-terminal lobe induces the bending of TM1, which in turn collapses the N-lobe cavity, thereby extruding the substrate drug to the extracellular space. Moreover, the macrocyclic peptides bind the central cleft in distinct manners, which correlate with their inhibitory activities. The strongest inhibitory peptide that occupies the N-lobe cavity may pave the way towards the development of efficient inhibitors against MATE transporters.
AB - Multidrug and toxic compound extrusion (MATE) family transporters are conserved in the three primary domains of life (Archaea, Bacteria and Eukarya), and export xenobiotics using an electrochemical gradient of H+ or Na+ across the membrane. MATE transporters confer multidrug resistance to bacterial pathogens and cancer cells, thus causing critical reductions in the therapeutic efficacies of antibiotics and anti-cancer drugs, respectively. Therefore, the development of MATE inhibitors has long been awaited in the field of clinical medicine. Here we present the crystal structures of the H+-driven MATE transporter from Pyrococcus furiosus in two distinct apo-form conformations, and in complexes with a derivative of the antibacterial drug norfloxacin and three in vitro selected thioether-macrocyclic peptides, at 2.1-3.0 Å resolutions. The structures, combined with functional analyses, show that the protonation of Asp 41 on the amino (N)-terminal lobe induces the bending of TM1, which in turn collapses the N-lobe cavity, thereby extruding the substrate drug to the extracellular space. Moreover, the macrocyclic peptides bind the central cleft in distinct manners, which correlate with their inhibitory activities. The strongest inhibitory peptide that occupies the N-lobe cavity may pave the way towards the development of efficient inhibitors against MATE transporters.
UR - http://www.scopus.com/inward/record.url?scp=84876297961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876297961&partnerID=8YFLogxK
U2 - 10.1038/nature12014
DO - 10.1038/nature12014
M3 - Article
C2 - 23535598
AN - SCOPUS:84876297961
SN - 0028-0836
VL - 496
SP - 247
EP - 251
JO - Nature
JF - Nature
IS - 7444
ER -